Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RX-10045 for ocular inflammation and pain after cataract surgery
NCT02329743Phase 2Completed
- Start
- Dec 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of navamepent in ocular inflammation (3 arms). Primary endpoint: Proportion of Subjects With Clearing of Anterior Inflammation at Day 8. Started Dec 2014; status: completed.
02
Drugs
navamepent
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT02329743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02329743.